RxDoctor Payments Data

Brandee Shipman

Psychiatric/Mental Health · Reno, NVNPI 1154914729

Payments from drug & device makers

$788in general payments, 2019–2025

Across 23 payments — averaging $34.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$429
  • Neurocrine Biosciences, Inc.$140
  • Jazz Pharmaceuticals Inc.$110
  • Otsuka America Pharmaceutical, Inc.$55
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25
  • Lundbeck LLC$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$788 in reported general payments places this provider in the 50th percentile of 362 psychiatric/mental health providers in Nevada.

See all psychiatric/mental health providers in Nevada

Medicare billing

Part B allowed, 2024
$42,633
Medicare patients
55
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole83$135,170
Invega SustennaPaliperidone Palmitate42$127,253
FanaptIloperidone12$41,860
Abilify MaintenaAripiprazole12$33,058
CaplytaLumateperone Tosylate12$22,618
Chlorpromazine Hcl13$11,702
Aripiprazole72$2,913
Quetiapine Fumarate118$2,831
Ziprasidone Hcl30$1,929
Oxcarbazepine34$1,829
Duloxetine Hcl55$1,812
Rivastigmine12$1,801
Risperidone91$1,747
Valproic Acid13$1,668
Zolpidem Tartrate ErZolpidem Tartrate13$1,658

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$55$168,22895 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$25$22,61812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 362 psychiatric/mental health providers in Nevada.

Other psychiatric/mental health in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →